EASD 2026: MiniMed touts Smart MDI system alert response benefits in type 1 diabetes patients

Type 1 diabetes patients with a higher response rates achieved time in range of over eight percentage points higher, on average. Type 1 diabetes patients with a higher response rates achieved time in range of over eight percentage points higher, on average. EASD 2026 took place in Milan, Italy between 28 September and 2 October. Credit: Volha Barysevich/Shutterstock.com Type 1 diabetes patients using MiniMed’s Smart Multiple Daily Injection (MDI) system who responded to more missed-dose and high-glucose alerts had, on average, 8.1 percentage points more time in range (TIR) and 0.6 percentage points lower HbA1c than lower responders, results from…

Source: Medical Device Network